%0 Journal Article
%A Rahbar, Kambiz
%A Essler, Markus
%A Pabst, Kim M
%A Eiber, Matthias
%A Fougère, Christian la
%A Prasad, Vikas
%A Rassek, Philipp
%A Hasa, Ergela
%A Dittmann, Helmut
%A Bundschuh, Ralph A
%A Fendler, Wolfgang P
%A Kurtinecz, Milena
%A Schmall, Anja
%A Verholen, Frank
%A Sartor, Oliver
%T Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study.
%J Journal of nuclear medicine
%V 64
%N 4
%@ 0097-9058
%C New York, NY
%I Soc.
%M DKFZ-2023-00703
%P 574 - 578
%D 2023
%X The radium lutetium (RALU) study evaluated the feasibility of sequential α- and β-emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer. Methods: This preplanned interim retrospective analysis investigated safety and survival outcomes with 177Lu-PSMA in patients treated with prior 223Ra. Results: Forty-nine patients were evaluated. Patients received a median of 6 223Ra injections; 59
%K Male
%K Humans
%K Lutetium: adverse effects
%K Radium: adverse effects
%K Prostatic Neoplasms, Castration-Resistant
%K Treatment Outcome
%K Retrospective Studies
%K Prostate: pathology
%K Prostate-Specific Antigen
%K Dipeptides: adverse effects
%K Heterocyclic Compounds, 1-Ring: adverse effects
%K 177Lu-PSMA (Other)
%K 223Ra (Other)
%K metastatic castration-resistant prostate cancer (Other)
%K real-world practice (Other)
%K targeted α-therapy (Other)
%K Lutetium (NLM Chemicals)
%K Radium (NLM Chemicals)
%K Prostate-Specific Antigen (NLM Chemicals)
%K Dipeptides (NLM Chemicals)
%K Heterocyclic Compounds, 1-Ring (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36302656
%2 pmc:PMC10071785
%R 10.2967/jnumed.122.264456
%U https://inrepo02.dkfz.de/record/275256